You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Aldesleukin

Showing 1 - 25 of 443
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor Trial in Seoul (TASO-001((TGF-ß2 targeting anti-sense oligonucleotide), Aldesleukin)

Recruiting
  • Solid Tumor
  • TASO-001((TGF-β2 targeting anti-sense oligonucleotide)
  • Aldesleukin
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Jan 31, 2023

Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma Trial run by the National Cancer Institute

Recruiting
  • Metastatic Melanoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 20, 2022

Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in Seattle (Aldesleukin,

Recruiting
  • Advanced Clear Cell Renal Cell Carcinoma
  • +3 more
  • Aldesleukin
  • Pembrolizumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 5, 2022

Chronic GVHD Trial in Duarte (biological, procedure, other)

Active, not recruiting
  • Chronic Graft Versus Host Disease
  • Aldesleukin
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Kidney Cancer Trial in Tampa (Pembrolizumab, Interleukin-2)

Active, not recruiting
Has Results
  • Kidney Cancer
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jun 21, 2022

Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7 Trial in United States

Active, not recruiting
Has Results
  • Clear Cell Renal Cell Carcinoma
  • +3 more
  • Aldesleukin
  • +6 more
  • Los Angeles, California
  • +3 more
Nov 16, 2022

Metastatic Renal Cell Carcinoma Trial in Boston (HD IL2)

Completed
Has Results
  • Metastatic Renal Cell Carcinoma
  • HD IL2
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Jun 20, 2022

HIV Trial run by the NIAID (Aldesleukin)

Completed
  • HIV Infections
  • Aldesleukin
  • Bethesda, Maryland
    Natl Inst of Allergy & Infect Dis / Cln Ctr
Oct 27, 2021

Alzheimer Trial in Houston (Aldesleukin)

Completed
  • Alzheimer Disease
  • Aldesleukin
  • Houston, Texas
    Alireza Faridar
Apr 19, 2023

Advanced Breast Cancer, Advanced Lung Cancer Trial (Tumor-infiltrating lymphocytes, IL-2)

Not yet recruiting
  • Advanced Breast Cancer
  • Advanced Lung Cancer
  • Tumor-infiltrating lymphocytes
  • IL-2
  • (no location specified)
Oct 26, 2023

Metastatic Malignant Tumor in the Liver, Metastatic Uveal Melanoma Trial in Houston (Aldesleukin, Autologous CD8+

Active, not recruiting
  • Metastatic Malignant Neoplasm in the Liver
  • Metastatic Uveal Melanoma
  • Aldesleukin
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 20, 2023

Leukemia Trial (biological, drug, procedure, radiation)

Active, not recruiting
  • Leukemia
  • aldesleukin
  • +9 more
  • (no location specified)
Feb 17, 2022

Neuroblastoma Recurrent Trial in Hong Kong (Natural killer cell, Dinutuximab beta, Interleukin-2)

Recruiting
  • Neuroblastoma Recurrent
  • Natural killer cell
  • +4 more
  • Hong Kong, Hong Kong
    Hong Kong Children's Hospital
Feb 22, 2023

HIV Infection Trial in Cleveland (Recombinant Interleukin-2)

Terminated
Has Results
  • HIV Infection
  • Recombinant Interleukin-2
  • Cleveland, Ohio
    AIDS Clinical Trials Unit
Sep 1, 2022

Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 Trial in Houston (biological,

Completed
  • Metastatic Melanoma
  • +3 more
  • Aldesleukin
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 27, 2022

Metastatic Non Small Cell Lung Cancer Trial in Raleigh (C-TIL051)

Not yet recruiting
  • Metastatic Non Small Cell Lung Cancer
  • C-TIL051
  • Raleigh, North Carolina
    Duke Cancer Institute
Jan 6, 2023

COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)

Active, not recruiting
  • COL6A3 Positive
  • +3 more
  • Aldesleukin
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 Trial in Houston

Active, not recruiting
  • Metastatic Melanoma
  • +2 more
  • Aldesleukin
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Cervical Cancer, Renal Cancer, Urothelial Cancer Trial run by the NCI (Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood

Completed
Has Results
  • Cervical Cancer
  • +4 more
  • Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Mar 2, 2022

Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer Trial run by the National Cancer Institute

Recruiting
  • Metastatic Colorectal Cancer
  • +4 more
  • Young TIL
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Metastatic Melanoma Trial run by the National Cancer Institute (NCI) (Aldesleukin, Fludarabine, Cyclophosphamide)

Completed
Has Results
  • Metastatic Melanoma
  • Aldesleukin
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 21, 2022

Metastatic Melanoma Trial in Tampa (procedure, drug, other)

Active, not recruiting
Has Results
  • Metastatic Melanoma
  • Surgery
  • +3 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center & Research Institute
Jan 10, 2023

Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Rochester

Not yet recruiting
  • Clinical Stage IV Gastric Cancer AJCC v8
  • +4 more
  • Aldesleukin
  • +10 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Apr 5, 2023

Kita-kyushu Lung Cancer Antigen 1, Human Trial run by the NCI (IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR)

Recruiting
  • Kita-kyushu Lung Cancer Antigen 1, Human
  • IL-2 (Aldesleukin)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 27, 2022

Metastatic Melanoma Trial in Burnsville (Aldesleukin: All Patients, Nivolumab: Cohort 1 (Cutaneous), Nivolumab: Cohort 2

Active, not recruiting
  • Metastatic Melanoma
  • Aldesleukin: All Patients
  • +3 more
  • Burnsville, Minnesota
    University of Minnesota Masonic Cancer Center
Feb 25, 2022